2 Iowa teens attend Type 1 diabetes Children's Congress in Washington, D.C.
DES MOINES, Iowa — Two teenagers from Iowa joined youth from across the world at the Breakthrough T1D Children's Congress in Washington, D.C. this weekend.
Every two years, the Children's Congress brings youth from across the world to Washington D.C. to share their Type 1 diabetes stories with Federal lawmakers. This year, the delegates are visiting from June 7 -9 and represent Breakthrough T1D groups across all 50 states, Australia, Canada, Israel, the Netherlands, and the United Kingdom.
Greek Food Fair Festival helps keep Church in community
The youth will act as delegates who share their stories and the stories of others, while engaging in leadership and advocating for continued research funding. This year, two delegates from Iowa, Elizabeth and Sachin, are sharing their stories.
Elizabeth, 17, is from Adel and was diagnosed with T1D at 14 years old, just days before the Super Bowl. She says seeing Noah Grey on the field reminded her that she could do anything. Elizabeth has built a T1D community through sharing tips and tricks, and hopes it helps others feel less alone. Elizabeth enjoys connecting with the community through her job and volunteering, she hopes to open her own business in the future.
Sachin, 13, was diagnosed with T1D at 10 and loves everything engineering. Sachin enjoys making fun inventions that bring laughter, and practical ones like a new kind of insulin pump he designed for his recent science fair project. Since his diagnosis, Sachin has attended walks, galas, and summits to support Breakthrough T1D and learn about exciting new technology that could help those living with Type 1 diabetes.
Visit the Breakthrough T1D website to learn more about the Children's Congress and the 170 delegates.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
U.S. Supreme Court orders review over religious challenge to New York abortion law
The U.S. Supreme Court on Monday ordered a lower court in New York to reevaluate whether some religious organizations should be excluded from a state mandate that requires employers to provide employee health care plans that include abortion coverage. The ruling from the high court said the case, Diocese of Albany v. Harris, should be sent back to New York courts to be reviewed again in light of an earlier unanimous Wisconsin case related to the Catholic Church groups being denied state tax exemptions. The justices pointed to the Wisconsin case because the New York case poses similar issues about states exempting religious employers and faith-based groups, The Associated Press reported. The New York case stems from a 2017 state mandate that requires health insurance plans provided by employers to include abortion coverage for situations that include rape and incest. The state mandate includes a religious exemption for institutions, but not for religious-affiliated groups. It was challenged by Catholic and Anglican nuns, Catholic dioceses, Christian churches and other faith organizations. They argued the religious exemption is so narrow that it violates the freedom of religion protected under the First Amendment. The most recent order from the Supreme Court is the second time the case has reached the justices after being litigated for years. After the state adopted the mandate in 2017, religious groups challenged it in state court. The appeals court upheld the regulation and the state refused to exempt religious organizations. In 2021, the religious groups appealed the state's ruling to the U.S. Supreme Court. Justices asked New York to reconsider based on its ruling in another case involving religion, Fulton v. Philadelphia. State courts found the Fulton decision was inapplicable to the situation, prompting the groups to bring it to the Supreme Court again. The religious liberty law firm Becket noted in a release that New York's exemption doesn't currently apply to some organizations, including the Carmelite Sisters for the Aged and Infirm and the Teresian Nursing Home because they 'serve the elderly and dying regardless of religious affiliation.' 'New York wants to browbeat nuns into paying for abortions for the great crime of serving all those in need,' Becket Vice President and senior counsel Eric Baxter said in a statement.' Following the Supreme Court's Monday order, the case is headed back to the New York Court of Appeals.
Yahoo
an hour ago
- Yahoo
Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 10 biotech stocks screaming a buy. On June 12, the company announced the upcoming retirement of Richard Geary, Ph.D., its executive vice president and chief development officer, effective January 2026. Holly Kordasiewicz, Ph.D., currently senior vice president of neurology, will take over the role. Geary has been with Ionis since 1995 and played a pivotal role in bringing six medicines to regulatory approval, including the company's first independently commercialized drug, TRYNGOLZA. A biotechnologist pouring liquid into a test tube and analyzing its components in a lab. Dr. Kordasiewicz, who joined Ionis in 2011, brings over 20 years of experience in R&D, particularly in neurology. She leads the company's neurology program, covering treatments for conditions such as Alzheimer's disease, Angelman syndrome, and Alexander disease. Her work has also contributed to key partnered programs with Biogen, including the development of QALSODY® and IONIS-MAPTRx. As Dr. Geary transitions out of his role, he will continue as a strategic consultant through 2026 to ensure continuity. Ionis leadership praised both Geary's legacy and Kordasiewicz's appointment as a pivotal step in driving the company's commitment to developing transformational therapies for patients with serious diseases. Ionis Pharmaceuticals, Inc. is a U.S.-based commercial-stage biotech company specializing in RNA-targeted therapies. Its approved products include TRYNGOLZA for FCS, WAINUA, and TEGSEDI for ATTRv-PN, SPINRAZA for spinal muscular atrophy, QALSODY for ALS, and WAYLIVRA for rare lipid disorders. The company has a robust pipeline, including late-stage programs like Olezarsen (for hypertriglyceridemia), Donidalorsen (for hereditary angioedema), and Zilganerse (for Alexander disease), along with several mid-stage treatments for neurological and metabolic conditions. Ionis also collaborates with leading pharma firms, including Biogen, GSK, AstraZeneca, Novartis, Roche, and Metagenomi, expanding its reach in developing transformative RNA therapies. While we acknowledge the potential of IONS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None.
Yahoo
an hour ago
- Yahoo
Acadia Pharmaceuticals (ACAD) Conducts Inducement Awards to Attract and Retain Top Talent
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is one of the 10 biotech stocks screaming a buy. On June 17, the company moved to attract and retain top talent by granting inducement awards to 41 employees. Under the 2024 Inducement Plan, the company will award the employees non-qualified stock options of 187,664 shares and 89.582 restricted stock units designed to attract and retain talent. A pharmacist in a pharmacy preparing a prescription medication for a patient suffering from Fibromyalgia. The move to offer inducement awards is part of Acadia Pharmaceuticals' push to secure top-skilled professionals essential for its neuroscience projects. It expects the awards to ensure employees are incentivized to contribute to the long-term objectives expected to lead to sustained growth and innovation. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharma company dedicated to advancing treatments for central nervous system disorders and rare diseases. Its key products include NUPLAZID, approved for Parkinson's disease psychosis, and DAYBUE. While we acknowledge the potential of ACAD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
